Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 13 papers were listed this time. Here's a handful in our areas of research interest:
Mullins CD, Hsiao FY, Onukwugha E, et al. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients. Cancer. 2011 Oct 21. [Epub ahead of print] PubMed PMID: 22020739.
Valentine WJ, Palmer AJ, Lammert M, et al. Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents. Clin Ther. 2011 Oct 19. [Epub ahead of print] PubMed PMID: 22018679.
Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer. 2011 Oct 25;105(9):1273-8. Epub 2011 Sep 29. PubMed PMID: 21959871.